Aytu Biopharma, Inc. AYTU
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.42% | -32.74% | -6.51% | -16.21% | 3.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.42% | -32.74% | -6.51% | -16.21% | 3.71% |
| Cost of Revenue | 16.72% | -14.77% | 1.95% | 2.46% | 37.84% |
| Gross Profit | 1.51% | -40.66% | -10.77% | -23.35% | -7.22% |
| SG&A Expenses | 22.98% | 17.19% | 13.86% | -4.99% | -10.30% |
| Depreciation & Amortization | -17.37% | -17.28% | -42.89% | -51.79% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.47% | 2.77% | 3.23% | -7.94% | -3.07% |
| Operating Income | -221.41% | -267.86% | -421.16% | -930.14% | 277.29% |
| Income Before Tax | 99.98% | -246.88% | -2,870.68% | 31.17% | -666.38% |
| Income Tax Expenses | -97.48% | 108.20% | -- | -- | -48.04% |
| Earnings from Continuing Operations | 99.92% | -242.59% | -1,691.58% | 79.78% | -488.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 105.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 99.92% | -240.66% | -1,443.15% | 33.31% | -329.24% |
| EBIT | -221.41% | -267.86% | -421.16% | -930.14% | 277.29% |
| EBITDA | -83.65% | -179.37% | -218.71% | -159.01% | 75.77% |
| EPS Basic | 99.97% | -182.09% | -920.70% | -14.33% | -255.16% |
| Normalized Basic EPS | 99.99% | -185.71% | -480.54% | -44.64% | -30,161.76% |
| EPS Diluted | 99.89% | -358.71% | -301.60% | 49.97% | -255.16% |
| Normalized Diluted EPS | 99.99% | -214.65% | -626.86% | -59.73% | -30,161.76% |
| Average Basic Shares Outstanding | 184.52% | 71.35% | 63.67% | 55.59% | 20.85% |
| Average Diluted Shares Outstanding | 184.52% | 28.12% | 18.28% | 114.04% | 20.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |